According to filings with the U.S. Securities and Exchange Commission, Gilgamesh Pharmaceuticals is raising $39,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jonathan Sporn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gilgamesh Pharmaceuticals
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.

To learn more about Gilgamesh Pharmaceuticals, visit http://www.gilgameshpharmaceutical.com/

Contact:
Jonathan Sporn, President and Chief Executive Officer
347-967-6831
https://www.linkedin.com/in/jonathan-sporn-4ba7802/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved